A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

As research continues and coverage improves, tirzepatide may become a cornerstone of obesity care — but only if patients can afford to access it.

those on tirzepatide saw an 18.4 cm (7.2 inches) reduction in waist circumference, compared to 13 cm (5.1 inches) for semaglutide. That difference of more than 2 inches is meaningful. Research ...

Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "Global Sustainable Aviation Fuel (SAF) Production Capacity Outlook to 2030 (2025 Edition)" report has been added to ResearchAndMarkets.com's offering.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

SAF Holland reported a revenue decline of 11% year-over-year for Q1 2025, reaching €449.2 million. Despite the revenue drop, the company maintained a robust adjusted EBIT margin of 9.5%.

Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "United States Biodiesel Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com ...

A majority of pet owners would prefer to spend time with their fluffy friends when they are stressed rather than with their partners, according to new research. A global survey of 30,000 pet ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

Research backs up this frustrating fact ... to-head comparison of the injectable GLP-1 medications semaglutide and tirzepatide, which are sold under the brand names Wegovy and Zepbound for ...

"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking on its effects on cardiovascular outcomes," said Packer. "This is the ...